Journal article

Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab

GA Kennedy, JF Seymour, M Wolf, H Januszewicz, J Davison, C McCormack, G Ryan, HM Prince

EUROPEAN JOURNAL OF HAEMATOLOGY | WILEY | Published : 2003

Abstract

OBJECTIVES: Alemtuzumab (anti-CD52, Campath-1H) has recently been shown to be effective in the treatment of a range of hematological malignancies, including B-cell chronic lymphocytic leukemia and T-cell prolymphocytic leukemia. We undertook a phase II study to evaluate the safety, tolerability and efficacy of alemtuzumab in patients with relapsed or refractory advanced stage cutaneous T-cell lymphoma. PATIENTS AND METHODS: A total of eight patients were enrolled, seven with mycosis fungoides/Sézary syndrome (MF/SS) and one with large-cell transformation of MF. Seven patients had disease refractory to multiple previous therapies. Alemzumab (30 mg) was administered intravenously three times p..

View full abstract